Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

 

Source:  Mangoceuticals, Inc. 3/25/2025

Diabetinol^® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace

Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the “Agreement”) to secure the exclusive licensing and distribution rights for Diabetinol^® within the United States and Canada.

Diabetinol^® is a plant-based nutraceutical clinically supported and patented extract of citrus peel rich in polymethoxylated flavones (PMFs), including nobiletin and tangeretin. Based on clinical studies performed, these compounds have demonstrated significant metabolic effects, particularly in how the body processes and utilizes sugar and fat. Mechanistically, Diabetinol^® works by improving insulin sensitivity, enhancing GLUT4-mediated glucose uptake in tissues, suppressing hepatic glucose production, and activating key enzymes involved in lipid metabolism. It also reduces systemic inflammation and oxidative stress—two of the primary biological drivers of insulin resistance and metabolic dysfunction.

Under the agreement, Mangoceuticals will hold the exclusive rights to market and sell Diabetinol^® across the United States and Canada, expanding its product portfolio into the $33.66 billion addressable diabetes and metabolic health market.

“Millions of people are left on the sidelines watching others lose weight using drugs they can’t afford,” said Jacob Cohen, Founder and CEO of Mangoceuticals, Inc., who continued, “Diabetinol^® is not a direct substitute for those prescription therapies, but the internal studies have concluded that it does offer complementary metabolic benefits in a safe, natural, and more affordable way. By harnessing clinically proven plant-derived ingredients, we’re providing a new option for individuals who cannot access or tolerate GLP-1 medications. Our goal is to help more people take control of their blood sugar and weight – safely, conveniently, and cost-effectively.”

Mangoceuticals’ expansion into metabolic health is timely given the escalating diabetes crisis and the enormous total addressable market for such solutions. In the U.S. alone, over 30 million Americans suffer from type 2 diabetes, and approximately 97.6 million American adults—more than one in three—have prediabetes. Globally, an estimated 537 million adults are currently living with diabetes, and that number is expected to rise to 783 million by 2045. If current trends continue, projections suggest it could exceed 1.3 billion by 2050.

The healthcare burden associated with this is immense. U.S. diabetes-related healthcare costs are already over $400 billion per year. Meanwhile, global spending on weight loss and blood sugar–lowering medications reached $24 billion in 2023 and is projected to surpass $131 billion by 2028. Currently, many people are prescribed metformin yet discontinue second-line therapies due to cost or tolerability. With an estimated 50% of Americans actively trying to lose weight at any given time, the demand for safer, more affordable metabolic health solutions is surging.

We believe that Diabetinol^® is well-positioned to fill that gap. As a naturally derived, clinically supported nutraceutical, it offers a compelling option for consumers who either can’t tolerate or access GLP-1 drugs, or who are seeking to support their health with a non-pharmaceutical approach.

Mangoceuticals intends to distribute Diabetinol^® in multiple consumer-friendly formats including capsules, a ready-to-drink beverage, quick-release pouches, cookies, and gummies. Each product will be carefully dosed to deliver consistent clinical levels of Diabetinol’s active ingredients. Distribution is expected to include direct-to-consumer online initiatives via our own website and through online retailers, brick and mortar retail outlets, and affiliate marketing channels.

Najla Guthrie, Founder of KGK Synergize and a recognized leader in nutraceutical clinical research, expressed strong support for Diabetinol’s role in addressing metabolic dysfunction, “I believe that Diabetinol^® has the potential to revolutionize how we think about supporting metabolic health. Its unique blend of natural citrus-derived compounds has been shown to deliver meaningful improvements in glycemic control, lipid profiles, and blood pressure—offering a safe and clinically validated adjunct to conventional care for those with prediabetes or diabetes,” said Guthrie. She further noted that Diabetinol’s formulation, centered around compounds like nobiletin and tangeretin, has been shown in rigorous clinical trials to improve glucose tolerance and lipid levels without adverse impacts on liver, kidney, or other organ functions and believes that these findings support Diabetinol as a safe, science-backed option to help manage blood sugar and reduce risk factors associated with cardiovascular disease.

Mr. Cohen further added, “Obtaining the exclusive rights to Diabetinol is a major milestone for Mangoceuticals. We are proud to introduce an innovative, science-backed nutraceutical that aligns with our mission of improving lives through safe and accessible wellness solutions. Diabetinol’s arrival could not be more timely, as the world faces a metabolic health epidemic and we have seen that patients are seeking alternatives that are both effective and affordable. We believe Diabetinol^® can become an invaluable option for individuals looking to take charge of their metabolic health, and we’re excited to lead that charge.”

In recent years, there has been growing public awareness around the need for cleaner, more natural approaches to health and wellness. Leaders in the national health conversation, including newly appointed United States Secretary of Health and Human Services, Robert F. Kennedy Jr., have emphasized the importance of reducing reliance on synthetic pharmaceuticals in favor of preventive, plant-based solutions, where appropriate. We believe that Diabetinol^® reflects this shift—offering a science-backed, naturally derived option for those seeking to support their metabolic health with fewer chemicals and greater transparency.

About Diabetinol^® Clinical Studies

In a 3-month pilot study involving participants with impaired glucose metabolism, Diabetinol^® was shown to reduce peak postprandial blood glucose by approximately 50 mg/dL following a glucose challenge test. This reduction is considered clinically meaningful, as it eases the burden on pancreatic beta cells and lowers the risk of long-term damage caused by repeated glucose spikes. Diabetinol^® helped participants stabilize blood sugar responses after meals, which is essential for preserving insulin function and preventing complications associated with hyperglycemia.

In a 6-month randomized, double-blind, placebo-controlled study of patients with type 2 diabetes or prediabetes who were already on conventional medications, Diabetinol^® was shown to significantly improve a range of health markers. Among those taking Diabetinol^®, 14.3% reached Hemoglobin A1c (HbA1c) targets (compared to 0% of the placebo group), 33.3% reached LDL cholesterol goals (vs. 15.4% placebo), 20% reached total cholesterol goals (vs. 12.5% placebo), and 83.3% reached systolic blood pressure goals (vs. 60% placebo). Participants also experienced improved glucose tolerance over time, with a slower rise in fasting glucose levels and improved Oral Glucose Tolerance Test (OGTT) profiles—especially in individuals aged 40 to 60.

More information about Diabetinol^® and the above clinical studies can be found online at www.Diabetinol.com.

About Mangoceuticals, Inc.

Mangoceuticals, Inc. is focused on developing a variety of men’s and women’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management for men under the brands “MangoRx” and weight management products for women under the brand “PeachesRx”. Interested consumers can use MangoRx’s or PeachesRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s and/or PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com. To learn more about PeachesRx, please visit www.PeachesRx.com.

Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

 

Source:  Mangoceuticals, Inc. 2/20/2025

Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women’s health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women’s unique health needs. These new and innovative women’s health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com.

PeachesRx will debut with a strong focus on compounded GLP-1 receptor agonists—a class of medications proven to aid weight loss by regulating appetite and glucose metabolism. Recent studies show that approximately 70% of GLP-1 prescriptions for weight loss are written for women, reflecting their dominant role in driving the surge in demand for these medications. By introducing its tailored GLP-1 offerings, PeachesRx aims to meet the unique metabolic needs of women while providing an accessible and affordable telehealth-driven solution.

Market demand for GLP-1 weight loss treatments among women is expanding rapidly. Industry projections estimate that the global GLP-1 market for weight management will exceed $48 billion by 2030, with women comprising the majority of users. Additionally, the global women’s health market was valued at $49.33 billion in 2024 and is projected to reach $68.53 billion by 2030, growing at a 5.1% CAGR. Within the U.S. women's telehealth market, growth is fueled by increased awareness, the demand for remote care, and the rise of personalized medicine. PeachesRx is well-positioned to capture this market by delivering GLP-1 solutions tailored to women's health needs, with seamless access through its HIPAA-compliant telemedicine platform.

"The launch of PeachesRx is the natural next step in Mangoceuticals’ expansion as we continue to redefine direct-to-consumer healthcare solutions," said Jacob Cohen, CEO and Founder of Mangoceuticals, who continued, "We’ve seen the success of our telehealth platform for men, and we believe there is an even greater opportunity in women’s health. As we have seen with MangoRx in the men’s health market, brand trust, accessibility, and innovative product offerings have been key to driving MangoRx’s success. PeachesRx will follow this blueprint, ensuring that women can confidently access clinically proven treatments tailored to their needs.”

Women represent a dominant force in telehealth adoption, with studies showing that over 60% of telehealth users are female. More than ever, women are seeking convenient, personalized healthcare solutions, and Peaches aims to revolutionize access by providing affordable, effective, and medically supervised treatments via its secure, HIPAA-compliant telemedicine platform.

"Women’s healthcare has been underserved for too long. With PeachesRx, we are transforming access by providing seamless, confidential, and medically backed care," said Amanda Hammer, COO of Mangoceuticals, who continued, "Our goal is to bring the same level of innovation, affordability, and accessibility that has driven our success in men’s wellness."

Positioned to be a leader in women’s telehealth, PeachesRx combines an intuitive user experience with a commitment to high-quality care, meeting the evolving needs of today’s healthcare consumers. By initially launching with GLP-1 solutions, PeachesRx intends to lay the groundwork for potential future expansion into broader wellness categories, including, but not limited to, sexual health, hair growth, and hormone therapy solutions. The Company plans to grow PeachesRx into a leader in women’s telehealth.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

About PeachesRx

PeachesRx is focused on developing a variety of women’s health and wellness products and services via a secure telemedicine platform. To date, the PeachesRx has identified weight management as the initial product category for its initial launch. Interested consumers can use PeachesRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about PeachesRx’s mission and other products, please visit www.PeachesRx.com.

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

 

Source:  Mangoceuticals, Inc. 2/12/2025

Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry.

The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India (“Vipragen”), to conduct independent efficacy studies aimed at developing an antiviral solution for respiratory illnesses in humans. These studies are based on the Company’s acquisition of patented respiratory illness prevention technology from IntraMont Technologies, Inc. (“IntraMont”). Phase I animal studies have already demonstrated significant efficacy in reducing lung viral load, and the compounds are now advancing into Phase II animal studies.

Mangoceuticals is leveraging this same technology to assess the feasibility of a drinking water-based application for poultry. The study is planned to focus on testing the efficacy of this solution when administered through drinking water and evaluating any necessary modifications to optimize its effectiveness in preventing avian flu infections among poultry populations.

Unlike traditional approaches that rely on synthetic vaccines or pharmaceutical treatments, Mangoceuticals' antiviral technology leverages Generally Recognized as Safe (GRAS) ingredients added to poultry drinking water. This method, we believe, may offer a simple, compliant, and non-pharmaceutical way to strengthen immune defenses in poultry. Following the Phase I animal studies, which concluded in late December, and pending promising results from the ongoing Phase II studies, though no assurances can be made, the Company believes this solution has the potential to be an effective tool in reducing the spread of H5N1 avian flu.

The ongoing avian flu outbreak has inflicted catastrophic losses on the poultry industry, leading to the culling of more than 148 million birds in the United States alone since 2022. These aggressive containment measures have crippled egg and poultry production, disrupted global supply chains, and sent consumer prices soaring. As of December 2024, the national average price of eggs hit $4.15 per dozen, with forecasts predicting an additional 20% increase in 2025.

In addition to direct losses from outbreaks, farms are extending significant amounts of resources on biosecurity measures and disease prevention strategies to protect flocks. Despite these costly efforts, avian flu remains a persistent threat, requiring a more effective and cost-efficient approach. Mangoceuticals' water-based antiviral technology aims to significantly reduce these expenses by hopefully providing a proactive, scalable, and easily deployable solution to help prevent infections before they spread.

"The rise in global avian flu outbreaks is not just an agricultural issue, it’s a potential global health crisis," said Jacob Cohen, Founder and CEO of Mangoceuticals, who continued, "Our initial animal study research has indicated and already demonstrated significant efficacy in reducing viral loads in respiratory illnesses, and now we’re taking the next step to evaluate how this same technology may be applied through poultry drinking water as a preventive measure. We believe that if proven effective in studies, this could be a simple, everyday solution that fits seamlessly into existing poultry farming practices while reducing the financial strain on farmers."

With the global poultry market projected to reach $375.41 billion by 2030, we believe that Mangoceuticals' water-based antiviral solution could, if proven successful in further studies, revolutionize disease prevention in livestock and provide poultry farmers with a powerful new tool against avian flu while helping to lower industry-wide costs.

As outbreaks continue to rise, Mangoceuticals remains committed to delivering effective, simple, and scalable solutions that protect livestock, stabilize the food supply, and prevent future pandemics. The Company anticipates sharing final study results upon completion of the study, while ensuring proper intellectual property protections ahead of commercialization.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

 

Source:  Mangoceuticals, Inc. 2/6/2025

Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences (“Vipragen”), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies, Inc. (“Intramont”).

Building on strong preliminary results, the Company is advancing to the next stage of research while also engaging Vipragen to structure a cohort for evaluating its patented respiratory illness prevention technology against the H5N1 virus (Avian Influenza). The H5N1 cohort is intended to run concurrently with the ongoing H1N1 study.

This milestone follows promising results from the initial H1N1 animal trial, which demonstrated a significant reduction in viral load. These findings underscore the potential of the technology and provide a strong foundation for continued exploration and expanded applications. The H1N1 and forthcoming H5N1 studies utilize Mangoceuticals’ proprietary formulation of advanced polyphenol and zinc chemistry.

Jacob Cohen, Founder and CEO of Mangoceuticals, commented: “Our ability to progress with this study reflects the robust potential of our innovative platform. The inclusion of H5N1 as part of the next leg of our research allows us to address another pressing global health concern while demonstrating our commitment to groundbreaking solutions for respiratory illnesses.”

Dr. Douglas Christianson, the Company’s Director of Medical Research and Product Innovation, added: “This next phase of advancement for H1N1 and the development of an H5N1 cohort highlight the versatility of our platform technology. These initiatives reaffirm our dedication to addressing evolving viral threats through innovation and cutting-edge research.”

With respiratory infections posing a growing global health concern, Mangoceuticals remains committed to leveraging its patented technology to combat these threats effectively. The company anticipates disclosing the final results of its studies upon completion and after ensuring proper intellectual property protections through provisional filings.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

 

Source:  Mangoceuticals, Inc. 2/3/2025

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol^®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.

Dermytol^® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol^® utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The patented formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.

The efficacy of Dermytol^® as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol^® was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the study, this would make Dermytol® a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.

The global skincare market is projected to reach approximately $218 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029. Within this expansive market, the plant-based skincare segment is experiencing significant growth. The global plant-based skincare products market, valued at $789.75 million in 2023, is expected to grow to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade. This surge is driven by consumer demand for natural, science-backed skincare solutions that offer visible results without compromising skin health.

Consumers are increasingly prioritizing products that promote healthier, more sustainable options, driving the market for non-retinol skincare solutions. Dermytol^®️ is poised to meet this demand with its innovative, clinically proven formulations, addressing a significant gap in the market for safe and effective solutions for hyperpigmentation, dark spots, and uneven skin tone

Jacob Cohen, CEO of Mangoceuticals, Inc., expressed enthusiasm for the partnership, stating: “We are thrilled to add Dermytol^®️ to our growing portfolio of high-performance wellness products. The demand for effective, natural skincare solutions is on the rise, and this collaboration allows us to bring a scientifically advanced product to market that aligns perfectly with our mission of delivering high-quality health and wellness solutions.”

Peter Polimeneas, CEO of Propre Energie Inc., added: “This agreement is a significant milestone for Dermytol^®️ as we expand into new markets with the support of a strong and experienced partner. Mangoceuticals’ expertise in digital marketing and e-commerce, combined with their dedication to quality, makes them the ideal distributor for our brand.”

Through this agreement, Mangoceuticals secures exclusive rights to market, sell, and distribute Dermytol^® across North and South America. The product will be available in both patch and cream formulations, offering versatile treatment options for consumers seeking to improve their skin’s radiance and overall health. Mangoceuticals aims to leverage its robust marketing and distribution infrastructure to accelerate Dermytol^®’s penetration in key markets.

About Propre Energie, Inc.

Propre Energie Inc. is a Quebec-based company specializing in plant-based, non-retinol skincare solutions under the Dermytol^®️ brand. With a focus on research and innovation, Propre Energie is dedicated to developing clinically proven, safe, and effective skincare products for individuals seeking healthier skin.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

Merck KGaA, Darmstadt, Germany, and p-Chip Successfully Implement Joint Solution to Bridge Gap Between Physical and Digital Trust Layers

 

Source:  Merck KGaA, Darmstadt, Germany 11/28/2023

• In collaboration, Merck KGaA, Darmstadt, Germany, and p-Chip Corporation are advancing a digital platform combining software and hardware components that allows customers to create digital twins of single physical products and prove their authenticity throughout the product life cycle
• The combined solution enables the usage of p-Chip microtransponders as crypto-anchors and facilitates the seamless integration of corresponding reader devices into customers' existing processes, ensuring digital authenticity and trust

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced today announced the successful integration of p-Chip Corp’s, Chicago, U.S.A., microtransponder technology as a crypto-anchor into a cyber-physical trust framework solution that is currently being developed by Merck KGaA, Darmstadt, Germany. This achievement marks an important milestone in enabling the creation of secure digital twins of physical products while ensuring their authenticity throughout their lifecycle.

“We are committed to empowering companies to fully leverage the advantages of the Industrial Internet of Things and develop digital twins of single objects they can really trust. Our solution, in collaboration with p-Chip Corporation, comprises a comprehensive combination of both software and hardware elements. This integrated approach enables our customers to effortlessly develop their individual digital applications, tailored to their unique requirements,” explained Thomas Endress, Executive Director of EMD Digital at Merck KGaA, Darmstadt, Germany. “By offering a secure and user-friendly platform, our solution ensures seamless interoperability while providing the flexibility and ease of integration that our customers demand.”

With its extensive expertise in highly regulated industries such as healthcare, life science, and electronics that require best product quality, Merck KGaA, Darmstadt, Germany, is uniquely positioned to deliver a solution that addresses complex application needs. Joe Wagner, CEO at p-Chip Corporation, added: “We are pleased that the powerful innovations planned through this strategic cooperation are coming to fruition. p-Chip microtransponders play an integral role in the robust digital solution of Merck KGaA, Darmstadt, Germany. As industries leverage blockchain, artificial intelligence, and machine learning to solve complex challenges, p-Chip's digital twin enabling technology delivers the breakthrough levels of visibility, traceability, and security needed for companies to achieve dramatic operational efficiencies and brand security.”

The cyber-physical trust framework solution aims to empower companies to harness the advantages of the Industrial Internet of Things (IIoT) with utmost confidence. It securely anchors physical objects to their digital identities, providing a reliable platform for product authentication and trust. The solution combines software and hardware components and seamlessly integrates into existing workflows and processes.

Companies can build their applications on the robust software foundation of the solution which utilizes multiple blockchain layers, crypto anchors, digital certificates, and smart contracts. By establishing a “single source of truth”, the cyber-physical trust framework facilitates seamless machine-to-machine communication, empowering ecosystem partners to achieve full traceability and digital trust while retaining control of their data.

Crypto anchors play a crucial role in securely identifying and authenticating physical objects within the cyber-physical trust framework. As a crypto-anchor agnostic solution, various types of crypto anchors are deployed, from conventional QR codes to RFID and high-security options such as the Securalic® security pigments of Merck KGaA, Darmstadt, Germany. The latter are of particular importance in highly regulated industries where errors due to incorrect product attribution are a problem. The addition of p-Chip microtransponders offers a highly secure and durable option to address increased security needs. Designed with a remarkably small footprint of only 500x500x100 μm, p-Chip microtransponders utilize a photocell for power and clock pulses, eliminating the need for induction coils or oscillators.

Moreover, the p-Chip microtransponders offer the added advantage of usability in challenging environments where other solutions may be impractical, such as harsh environments that would damage or decompose other taggant solutions. These microtransponders can be directly applied to products including metal, circumventing issues related to label detachment.

Together with p-Chip Corporation, wireless handheld readers have been developed that are designed for seamless integration into existing processes via Bluetooth connectivity enabling portable and hassle-free scanning. The integration of these readers represents a significant milestone, demonstrating that different crypto anchors with their respective advantages can be unified on a single technical platform, offering a harmonized user experience. As a result, customers can choose a combination of technologies that best suits their products and processes.

About p-Chip Corporation

Since 2017, p-Chip Corporation has revolutionized the tracking of physical products and materials with its breakthrough microtransponder technology. Highly durable and small as a grain of salt, its uniquely traceable, light-activated p-Chip crypto anchor functions like a digital twin for physical items. This silicon microchip authenticates goods across the supply chain and enables secure tracking of data through web, cloud, or blockchain applications. From life sciences and healthcare to electronics, automotive components, food ingredients, and more, organizations worldwide look to patented p-Chip microtransponders to securely track chain-of-custody, unlock business intelligence, protect brand and product integrity, and enhance revenue. To learn more, visit www.p-Chip.com.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement

 

Source:  Data Vault Holdings, Inc. 7/25/2023

Microtransponder Technology Adds to Web 3.0 Anchor Options and a Host of Capabilities to DataVault's Data Management Platform

Data Vault Holdings, Inc., the emerging leader in metaverse data visualization, valuation, and the monetization of data assets, and p-Chip Corporation, a company that is revolutionizing the tracking of physical products and materials with its breakthrough microtransponder technology, today announced they have signed a Letter of Intent (LOI) for an Intellectual Property Licensing Agreement.

Under the terms of the agreement, Data Vault Holdings will develop solutions that integrate its proprietary ADIO® and DataVault® technology platforms with p-Chip Corporation's light activated microtransponder technology platform. p-Chip Corporation is working with global leading companies to integrate its microtransponder technology as a digital twin enabler, including collaboration under a joint development agreement with Merck KGaA (FWB:MRK) and providing food-safe digital tracking solutions for the Consorzio del Parmigiano Reggiano.

The collaboration will focus on the integration of p-Chip Corporation's crypto anchor as a digital twin enabler for Data Vault's Web 3.0 platform, which provides businesses with the tools to monetize data assets securely over its Information Data Exchange®(IDE).

A comprehensive news release will be issued upon the signing of definitive agreements.

About Data Vault Holdings , Inc.

Data Vault Holdings Inc. is a technology holding company that provides a proprietary, cloud-based platform for the delivery of branded data-backed blockchain objects. DataVault®, the company's patented platform, provides businesses with the tools to monetize data assets securely over its Information Data Exchange® (IDE). The company owns Data Donate Technologies, Inc., ADIO LLC, Datavault Inc. and True Luck, Inc. as wholly owned subsidiaries under one corporate structure. Learn more about Data Vault Holdings Inc. at www.datavaultholdings.com.

About p-Chip Corporation

Since 2017, p-Chip Corporation has revolutionized the tracking of physical products and materials with its breakthrough microtransponder technology. Highly durable and small as a grain of salt, its p-Chip crypto anchor functions like a digital twin for physical items, delivering breakthrough visibility and security at a scalable price point. From pharmaceuticals to electronics, automotive components to agricultural ingredients, companies worldwide rely on patented p-Chip microtransponders to unlock business intelligence, protect brand and product integrity, and enhance revenue. To learn more, visit www.p-chip.com.